Aphios awarded SBIR grant for Alzheimer’s research

Wednesday, January 25, 2012 04:12 PM

Aphios has received a phase II SBIR grant from the National Institutes of Health (NIH) for $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to Aphios to develop an “Alzheimer’s Disease Therapeutic.

Alzheimer’s Disease (AD) is a devastating age-related neurological disorder and is the third leading cause of death in America and among the highest in the industrial world.

Aphios is developing APH-0703, a potent protein kinase C (PKC) modulator that activates the alpha-secretase pathway, which can dramatically enhance the generation of soluble amyloid precursor protein (sAPP), diminishing plaques and cognitive deficits associated with Alzheimer’s.

“We are developing novel formulations of APH-0703 based on Aphios’ proprietary hydrophobic-based formulation and patented SFS-PNS polymer nanospheres technologies,” explained Dr. Trevor P. Castor, president and CEO of Aphios. “After formulation selection, Aphios will manufacture and characterize the API and final drug product following cGMP guidelines, and conduct pre-clinical studies in preparation of filing an IND with the FDA to conduct human clinical trials.

Aphios is collaborating with researchers at Louisiana State University Health Sciences Center, Shreveport, La. (LSUHSC), which will conduct in vitro and in vivo efficacy, toxicity and pharmacokinetic studies in triple transgenic AD mice.

The project is supported by grant number R44AG034760 from the National Institute on Aging.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs